SARS-CoV-2 Antibody Seroprevalence and Humoral Response to Vaccination in Patients Undergoing Maintenance Hemodialysis: A Prospective Cohort Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.COVID-19 vaccination in hemodialysis patients showed a 64.7% seroconversion rate after two doses. This highlights the importance of assessing vaccine response in this vulnerable chronic kidney disease population.
Area Of Science
- Nephrology
- Immunology
- Infectious Diseases
Background
- Chronic kidney disease patients on maintenance hemodialysis are vulnerable to severe COVID-19.
- Prioritizing vaccination and assessing immune response in this cohort is crucial.
Purpose Of The Study
- To evaluate the antibody response to COVID-19 vaccination in patients with chronic kidney disease stage 5 on maintenance hemodialysis.
- To determine seroconversion rates and identify factors influencing vaccine response.
Main Methods
- Prospective analytical study of 96 hemodialysis patients receiving Covaxin or Covishield.
- Serum antibody titers measured pre-vaccination, post-first dose, and post-second dose.
- Seronegative and seropositive groups defined based on antibody levels (≥0.8 U/ml).
Main Results
- A high baseline seropositivity rate (indicating prior subclinical infection) was observed.
- After two vaccine doses, 64.7% of initially seronegative patients achieved seropositivity.
- A robust antibody response was noted in some patients, while 35.29% showed no antibody response after two doses.
Conclusions
- The study demonstrates a significant seroconversion rate following two doses of COVID-19 vaccines in hemodialysis patients.
- Findings underscore the need for continued monitoring and potential strategies to enhance vaccine efficacy in this immunocompromised population.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
